Total Neoadjuvant Therapy is a Current Trend in the Treatment of Locally Advanced Rectal Cancer
https://doi.org/10.17238/2072-3180-2024-1-85-91
Abstract
Introduction. Radiation therapy, which has long been a standard element of the neoadjuvant stage of combined treatment of locally advanced rectal cancer, has made significant progress in preventing local recurrence of the disease. The desire to improve the efficiency of local control, as well as to influence the risks of systemic relapse, led to the development of the concept of total neoadjuvant therapy.
Results. The article is a review of modern publications analyzing the results of the use of total neoadjuvant therapy. A number of recent randomized clinical trials have demonstrated the effectiveness of this approach, achieving an improvement in disease-free and overall survival, and a reduction in the incidence of distant metastasis of rectal cancer. At the same time, no negative impact of neoadjuvant chemotherapy on the frequency of radical resection, the quality of total mesorectumectomy, or the structure of postoperative complications was recorded. Similar results were noted in a number of published meta-analyses examining the effectiveness and safety of total neoadjuvant therapy.
Conclusions. The combination of radiation therapy and systemic chemotherapy in the preoperative period offers hope for improving the results of treatment of locally advanced rectal cancer. Indications for total neoadjuvant therapy, the optimal regimen and frequency of chemotherapy cycles currently still need to be clarified.
About the Authors
A. M. Karachun
N.N. Petrov Research Institute of Oncology ; I.I. Mechnikov North-Western State Medical University
Russian Federation
Russian Federation
Karachun Alexey Mikhailovich – Doct. Med. Sci., professor, head of the Department of Abdominal Oncology
197758, St. Petersburg, Pesochny, Leningradskaya Street, 68
D. V. Samsonov
N.N. Petrov Research Institute of Oncology ; St. Petersburg S.M. Kirov Military Medical Academy
Russian Federation
Russian Federation
Samsonov Denis Vladimirovich – Cand. Med. Sci., docent, oncologis
197758, St. Petersburg, Pesochny, Leningradskaya Street, 68
E. V. Zagaynov
N.N. Petrov Research Institute of Oncology
Russian Federation
Russian Federation
Zagaynov Evgeniy Vladimirovich – Cand. Med. Sci., oncologist
197758, St. Petersburg, Pesochny, Leningradskaya Street, 68
P. Yu. Grishko
N.N. Petrov Research Institute of Oncology
Russian Federation
Russian Federation
Grishko Pavel Yurievich – Cand. Med. Sci., researcher, Scientific Department of Diagnostic and Interventional Radiology
197758, St. Petersburg, Pesochny, Leningradskaya Street, 68
References
1. Boublikova L., Novakova A., Simsa J., Lohynska R. Total neoadjuvant therapy in rectal cancer: the evidence and expectations. Crit. Rev. Oncol. Hematol., 2023, № 192, рр. 104196. https://doi.org/10.1016/j.critrevonc.2023.104196
2. Johnson G.G.R.J., Park J., Helewa R.M. et al. Total neoadjuvant therapy for rectal cancer: a guide for surgeons. Can. J. Surg., 2023, № 66(2), рр. e196–e201. https://doi.org/10.1503/cjs.005822
3. Holch J.W., Demmer M., Lamersdorf C. et al. Pattern and dynamics of distant metastases in metastatic colorectal cancer. Visc. Med., 2017, № 33(1), рр. 70–75. https://doi.org/10.1159/000454687
4. Hu Z., Ding J., Ma Z. et al. Quantitative evidence for early metastatic seeding in colorectal cancer. Nat. Genet., 2019, № 51(7), рр. 1113– 1122. https://doi.org/10.1038/s41588-019-0423-x
5. Bahadoer R.R., Dijkstra E.A., van Etten B. et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol., 2021, № 22(1), рр. 29–42. https://doi.org/10.1016/S1470-2045(20)30555-6
6. Dijkstra E.A., Nilsson P.J., Hospers G.A.P. et al. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial. Ann Surg., 2023, № 278(4), рр. e766–e772. https://doi.org/10.1097/SLA.0000000000005799
7. Conroy T., Bosset J.-F., Etienne P.-L. et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol., 2021, № 22(5), рр. 702–715. https://doi.org/10.1016/S1470-2045(21)00079-6
8. Conroy T., Etienne P.-L., Rio E. et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial. J. Clin. Oncol., 2023, № 41(17), рр. suppl. https://doi.org/10.1200/JCO.2023.41.17_suppl.LBA3504
9. Ciseł B., Pietrzak L., Michalski W. et al. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol., 2019, № 30(8), рр. 1298–1303. https://doi.org/10.1093/annonc/mdz186
10. Jin J., Tang Y., Hu C. et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J. Clin. Oncol., 2022, № 40(15), рр. 1681–1692. https://doi.org/10.1200/JCO.21.01667
11. Fernandez-Martos C., Garcia-Albeniz X., Pericay C. et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial. Ann Oncol., 2015, № 26(8), рр. 1722–1728. https://doi.org/10.1093/annonc/mdv223
12. Garcia-Aguilar J., Chow O.S., Smith D.D. et al. Timing of rectal cancer response to chemoradiation consortium. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol., 2015, № 16(8), рр. 957–966. https://doi.org/10.1016/S1470-2045(15)00004-2
13. Kasi A., Abbasi S., Handa S. et al. Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis. J.A.M.A. Netw. Open., 2020, № 3(12), рр. e2030097. https://doi.org/10.1001/jamanetworkopen.2020.30097
14. Petrelli F., Trevisan F., Cabiddu M. et al. Total neoadjuvant therapy in rectal cancer: a systematic review and meta-analysis of treatment outcomes. Ann. Surg., 2020, № 271(3), рр. 440–448. https://doi.org/10.1097/SLA.0000000000003471
15. Liu S., Jiang T., Xiao L. et al. Total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta‐analysis. Oncologist, 2021, № 26(9), рр. e1555–e1566. https://doi.org/10.1002/onco.13824
16. Kong J.C., Soucisse M., Michael M. et al. Total neoadjuvant therapy in locally advanced rectal cancer: a systematic review and metaanalysis of oncological and operative outcomes. Ann. Surg. Oncol., 2021, № 28(12), рр. 7476–7486. https://doi.org/10.1245/s10434-021-09837-8
17. Xiong K., Bao T., Cao Y. et al. Efficacy and safety of total neoadjuvant therapy in locally advanced rectal cancer: a meta-analysis. Int. J. Colorectal. Dis., 2023, № 38(1), р. 89. https://doi.org/10.1007/s00384-023-04376-y
18. Garcia-Aguilar J., Patil S., Gollub M.J. et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol., 2022, № 40(23), рр. 2546–2556. https://doi.org/10.1200/JCO.22.00032.
19. Fokas E., Schlenska-Lange A., Polat B. et al. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO/ARO/AIO-12 randomized clinical trial. J.A.M.A. Oncol., 2022, № 8(1), рр. e215445. https://doi.org/10.1001/jamaoncol.2021.5445
20. Iveson T.J., Kerr R.S., Saunders M.P. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncol., 2018, № 19(4), рр. 562–578. https://doi.org/10.1016/S1470-2045(18)30093-7
21. Glynne-Jones R., Wyrwicz L., Tiret E. et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2017, № 28(suppl 4), рр. iv22–iv40. https://doi.org/10.1093/annonc/mdx224
22. Wo J.Y., Anker C.J., Ashman J.B. et al. Radiation therapy for rectal cancer: executive summary of an ASTRO clinical practice guideline. Pract. Radiat. Oncol., 2021, № 11(1), рр. 13–25. https://doi.org/10.1016/j.prro.2020.08.004
23. Polynovskiy A.V., Mammadli Z.Z., Kuzmichev D.V., etc. Preliminary results of the multicenter Russian randomized trial RUCORT3: treatment of patients with locally advanced rectal cancer (MRPC). Malignant tumors, 2022, № 12(3s1), pp. 69–75. (In Russ.) https://doi.org/10.18027/2224-5057-2022-12-3s1-69-75
24. Sychev S.I., Chernyshov S.V., Arzamastseva A.I. et al. Safety of the total neo-adjuvant therapy in rectal cancer treatment. Preliminary results of the randomized trial. Coloproctology, 2022, № 21(3), рр. 76–84. (In Russ.) https://doi.org/10.33878/2073-7556-2022-21-3-76-84.
Review
For citations:
Karachun A.M., Samsonov D.V., Zagaynov E.V., Grishko P.Yu. Total Neoadjuvant Therapy is a Current Trend in the Treatment of Locally Advanced Rectal Cancer. Moscow Surgical Journal. 2024;(1):85-91. (In Russ.) https://doi.org/10.17238/2072-3180-2024-1-85-91
Views:
574
Email this article 